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Abstract
Objectives We recently described metabolic nodal stage (mN) and response (mNR) of cancer of the esophagus and gastro-
esophageal junction (GEJ) to neoadjuvant chemotherapy (NAC) using 18F-FDG PET-CTas new markers of disease progression,
recurrence, and death. We aimed to validate our findings.
Methods Our validation cohort comprised all patients consecutive to our discovery cohort, staged before and after NAC using
PET-CT from 2014 to 2017. Multivariate binary logistic and Cox regression were performed.
Results Fifty-one of the 200 patients had FDG-avid nodes after NAC (25.5%; i.e., lack of complete mNR), and were more likely to
progress during NAC to incurable disease on PET-CTor at surgery: odds ratio 3.84 (1.46–10.1; p= 0.006). In 176 patients undergoing
successful resection, patients without complete mNR had a worse prognosis: disease-free survival hazard ratio 2.46 (1.34–4.50);
p = 0.004. These associations were independent of primary tumor metabolic, pathological response, and stage. In a hybrid
pathological/metabolic nodal stage, avid nodal metastases conferred a worse prognosis than non-avid metastases. Lack of complete
mNR predicted recurrence or death at 1 and 2 years: positive predictive values 44.4% (31.7–57.8) and 74.1% (56.6–86.3) respectively.
Conclusions This study provides temporal validation for mNR as a new and independent predictive and prognostic marker of
esophageal and GEJ cancer treated with NAC and surgery, although external validation is required to assess generalizability.
mNRmay provide surrogate information regarding the phenotype of metastatic cancer clones beyond the mere presence of nodal
metastases, and might be used to better inform patients, risk stratify, and personalize management, including adjuvant therapy.
Key Points
•We previously described metabolic nodal response (mNR) of esophageal cancer to neoadjuvant chemotherapy using 18F-FDG
PET-CT as a predictor of unresectable disease, early recurrence, and death.
• We report the first validation of these findings. In an immediately consecutive cohort, we found consistent proportions of
patients with and without mNR, and associations with abandoned resection, early recurrence, and death.
• This supports mNR as a new and actionable biomarker in esophageal cancer. Although external validation is required, mNR
may provide surrogate information about the chemosensitivity of metastatic subclones, and the means to predict treatment
success, guide personalized therapy, and follow-up.
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Abbreviations
BPL Bayesian penalized likelihood
CI Confidence interval
CMR Complete metabolic response
CT Computed tomography
DFS Disease-free survival
EUS Endoscopic ultrasound
FDG 18F-fluorodeoxyglucose
GE General Electric
GEJ Gastro-esophageal junction
MDT Multidisciplinary team
mN Metabolic nodal stage
mNR Metabolic nodal response
NPV Negative predictive value
mTR Metabolic tumor response
NAC Neoadjuvant chemotherapy
NHS National Health Service
OS Overall survival
OSEM Ordered subset expectation maximization
PERCIST Positron Emission Tomography Response
Criteria in Solid Tumors
PET-CT Positron emission tomography-computed
tomography
PMD Progressive metabolic disease
PMR Partial metabolic response
PPV Positive predictive value
SMD Stable metabolic disease
SUVmax Maximum standardized uptake value
ypN Pathological nodal stage after chemotherapy
ypT Pathological tumor stage after chemotherapy
Introduction
We recently reported the new concepts of metabolic nodal
stage (mN) and response (mNR) of esophageal and gastro-
esophageal junction (GEJ) cancer to neoadjuvant chemo-
therapy (NAC) [1, 2]. We found that patients with FDG-
avid nodes within a standard lymphadenectomy field on
18F-fluorodeoxyglucose (FDG) positron emission
tomography-computed tomography (PET-CT) that
persisted despite NAC (i.e. lacking a complete metabolic
nodal response, CMR) were more likely to suffer disease
progression during NAC which prevented resection (i.e.,
distant metastases, or locally unresectable disease).
Furthermore, if resection was performed successfully,
these patients were more likely to suffer disease recur-
rence. This was independent of pathological stage, and
both pathological and metabolic regression of the primary
tumor [1, 2], suggesting mNR to be a surrogate of regres-
sion of nodal metastases to NAC. Indeed, in some patients
notable disparity was seen between primary and nodal re-
sponse, suggesting mNR might represent a surrogate of the
chemosensitivity of different clones, and perhaps by ex-
trapolation occult distant metastatic clones.
mNR therefore represents a potentially novel and ac-
tionable biomarker of the success both of NAC and radical
lymphadenectomy, for which there is an urgent need [3–6].
Such a marker might have the potential to monitor re-
sponse to NAC and perhaps personalize therapy, while also
better prognosticating before surgery, and stratifying the
risk of recurrence thereafter. To our knowledge, no studies
have subsequently assessed mNR as a marker of disease
progression and recurrence. We aimed to perform the first
validation study of mNR as a marker of disease progres-
sion and recurrence, using a temporal cohort of patients
immediately consecutive to our discovery cohort.
Methods
Study design and approval
We routinely stage and restage patients with esophageal or
GEJ cancer using 18F-FDG PET-CT, and retrospectively iden-
tified all such patients receiving NAC from January 2014 to
June 2017. The study was approved by the Oxford University
Hospitals NHS Foundation Trust Research and Development
committee.
Inclusion and exclusion criteria
We included all patients with histologically confirmed cancer
of the esophagus or GEJ, staged in our institution with 18F-
FDG PET-CT, undergoing NAC before being restaged with
18F-FDG PET-CT. We excluded patients treated with neoad-
juvant chemoradiotherapy, as well as those undergoing PET-
CT in other centers.
Staging and restaging
All examinations were reported by subspecialist consultant
gastrointestinal radiologists and reviewed at a specialist
esophagogastric cancer multidisciplinary team (MDT)
meeting, using the TNM 7th edition [7]. Patients
underwent intravenous and oral contrast-enhanced CT
chest abdomen and pelvis, as previously reported [1, 2].
In the absence of unequivocal incurable disease, patients
then underwent PET-CT (see below), followed by laparos-
copy (without peritoneal cytology) for tumors extending
below the diaphragm. Endoscopic ultrasound (EUS) was
performed selectively. Examinations were reported.
Patients were restaged 4–6 weeks after NAC.
PET-CTwas performed from January 2014 using a General
Electric (GE) Discovery 690 64-slice system, then also a GE
Discovery 710 from September 2014 (both 90 min post
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4 MBq/Kg FDG), all using ordered subset expectation maxi-
mization (OSEM) reconstruction; after 1 November 2014, a
Bayesian penalized likelihood (BPL) reconstruction technique
was used (Q.Clear) without intravenous contrast. Any staging
studies initially reconstructed with OSEM and undergoing a
subsequent restaging examination with BPL had their baseline
studies reconstructed with BPL to ensure validity.
Examinations were independently reported by two dedicated
PET-CT radiologists, dual trained in nuclear medicine and
clinical radiology.
Data
PET-CT data comprised primary tumor maximum stan-
dardized uptake value (SUVmax), the presence and num-
ber of FDG-avid nodes (mN, as previously defined: mN1
1–2 avid nodes, mN2 > 2), in both cases, a target SUVmax
greater than mediastinal blood pool being avid [1];
restaging SUVmax (used to calculate metabolic tumor re-
sponse [mTR], % reduction SUVmax normalized for back-
ground SUVmax [2.5], and PERCIST classification [8]);
metastatic disease; mNR as previously defined (complete
metabolic response [CMR] to background mediastinal
blood pool avidity, partial metabolic response [PMR; re-
duction in mN stage or % reduction in nodal SUVmax
> 30%], stable metabolic disease [SMD; no change in
mN stage, or nodal SUVmax < 30%], and progressive met-
abolic disease [PMD; progression in mN stage, or increase
nodal SUVmax > 30%]).
Pathological data comprised pathological stage [7], and
primary tumor regression (Mandard tumor regression grade
1–3 being response, 4–5 no response [2, 9]). Survival data
comprised recurrence and death (censored on 23
March 2018). Disease progression to incurable disease during
NAC was defined as either metastatic disease on imaging
(confirmed by MDT discussion ± confirmatory imaging/his-
topathology) or unresectable disease at surgery (confirmed
intra-operatively by frozen section histopathology, or consen-
sus of two consultant surgeons).
Neoadjuvant chemotherapy
Patients received a variety of regimens based on MDT con-
sensus and trial enrolment: either 2 cycles of doublet therapy
(cisplatin/oxaliplatin and 5-fluorouracil/capecitabine) or 3 or 4
cycles of pre- ± post-operative triplet therapy (epirubicin,
cisplatin/oxaliplatin and 5-fluorouracil/capecitabine) as previ-
ously described [10–14].
Surgery
Esophagectomy (for esophageal or GEJ type I–II cancers)
or extended total gastrectomy (types II–III) was performed
typically 2 weeks after restaging, via left thoraco-
abdominal, Ivor-Lewis (right thoracotomy plus laparoto-
my/laparoscopy), and three-stage approaches (laparoto-
my/laparoscopy, thoracotomy plus neck dissection). A
minimum two-field lymphadenectomy was performed; for
mid/distal esophageal/type 1 GEJ tumors, this included
subcarinal, aortopulmonary window, and left gastric nodes,
and for distal/GEJ tumors, left gastric and common hepatic
artery nodes.
Follow-up
Patients were reviewed clinically at 2 and 6 weeks after
surgery, 3 months to 1 year and 6–12 months thereafter
for at least 5 years. Investigations for recurrence were per-
formed only on the basis of clinical suspicion, typically CT
or PET-CT for extra-luminal recurrence, and endoscopy for
luminal.
Statistical analysis
Analysis was performed using R v3.0.2 [15]. Groups were
compared using Fisher’s exact test. Univariate binary lo-
gistic and Cox regression analysis were performed using
all individual data fields. Multivariate binary logistic and
Cox regression were performed using variables with
p < 0.1 on univariate analysis for inclusion in the final
mu l t i va r i a t e mode l . The so l e pa t i en t w i th an
adenosquamous carcinoma was excluded from univariate
analysis of cell type, being a perfect separator. The final
multivariate binary logistic regression models for disease
progression comprised mTR and restaging mN; for
unresectable disease at surgery, restaging mN and pre-
treatment grade of differentiation; and for disease-
progression overall, restaging mN and clinical N stage.
The final multivariate Cox models for survival comprised
mNR, ypT, ypN, ypV (except for overall survival, as
p > 0.1 on univariate analysis), ypL, resection margin sta-
tus, pTR, and mTR. For the model assessing a pNmN
hybrid, the models were as above, having excluded
mNR and ypN due to multicollinearity. The final multi-
variate binary logistic regression model for early
recurrence/death comprised of mnR, ypT, ypN, ypL, re-
section margin status, pTR, and mTR. Similarly, the mod-
el assessing a pNmN hybrid excluded mNR and ypN.
Survival metrics were calculated using the Kaplan-Meier
method, and follow-up using the reverse Kaplan-Meier
method, excluding patients dying in hospital due to
post-operative complications. Kaplan-Meier curves were
generated using survfit (Survival Package v2.42-3) using
the log-rank test.
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Results
mN stage and response
Two hundred patients were included (Table 1). Eighty-one
(40.5%) had avid nodes before NAC. Thirty-eight (46.9%)
underwent CMR. Eight (4.00% overall) previously mN0 pa-
tients developed avid nodes. In total, 51 patients (25.5%) had
avid nodes following NAC. This was consistent with the de-
velopment cohort: 64/280 (22.9%; p = 0.617). PET recon-
struction algorithms did not influence mNR, mTR, and detec-
tion of metastatic disease (Supplementary Table 1).
Progression to incurable disease on restaging PET-CT
Incurable disease was identified in 10 (5.00%) patients. No
pre-treatment factors were associated with this. On multivari-
ate binary logistic regression, both the presence of avid nodes
at restaging (mN stage 2) and lack of mTR (% reduction in
primary tumor SUVmax) were associated with coexistent
metastatic disease (Table 2). Five of 51 (9.80%) patients with
avid nodes after NAC hadmetastatic disease, comparedwith 5
of 149 (3.36%) without (p = 0.127).
Progression to unresectable disease at surgery
A further 2 patients without metastases evident on restaging
PET-CT did not proceed to surgery for medical reasons (both
had avid nodes). One hundred eighty-eight proceeded to sur-
gery. Unsuspected unresectable disease was encountered in 10
(5.32%). On multivariate analysis, this was associated with
the presence of avid nodes following NAC: OR 7.67 (1.94–
30.4; p = 0.004; Table 2).
Disease progression overall
Overall, avid nodes following NAC predicted disease progres-
sion: OR 3.84 (1.46–10.1; p = 0.006), independent of all var-
iables including clinical N stage. As with progression on PET-
CT, this association was primarily seen for patients with mN2
disease after NAC.
Predicting unresectable disease at surgery
Before surgery, 44 of 188 patients (23.4%) had avid nodes
following NAC. Of these, 6 (14.0%) had an abandoned resec-
tion, compared with 4 of 144 without (2.78%; p = 0.011; 6
true positives, 38 false positives, 4 false negatives, and 140
true negatives) The presence of avid nodes despite NAC was
60.0% sensitive (26.2–87.8) and 78.7% specific (71.9–84.4)
for predicting unsuspected unresectable disease. Positive pre-
dictive value (PPV) was 13.6% (8.13–22.0), and negative pre-
dictive value (NPV) was 97.2% (94.2–98.9%).
Table 1 Patients
Characteristic All patients
(n = 200)
Survival analysis
(n = 176)
Age (median, IQR) 70.0 (63.0–74.0) 70.0 (63.0–74.0)
Gender
Male 159 (79.5%) 137 (77.8%)
Female 41 (20.5%) 39 (22.2%)
Tumor cell type
AC 183 (91.5%) 161 (91.5%)
SCC 16 (8.00%) 14 (7.95%)
AS 1 (0.50%) 1 (0.58.%)
Grade of differentiation
Well 4 (2.00%) 3 (1.70%)
Moderate 93 (46.5%) 86 (48.9%)
Poor/undifferentiated 103 (51.5%) 87 (49.4%)
Tumor site
Mid esophageal 15 (7.50%) 12 (6.82%)
Distal esophageal 77 (38.5%) 67 (38.1%)
GEJ1 55 (27.5%) 53 (29.5%)
GEJ2 29 (14.5%) 25 (14.2%)
GEJ3 24 (12.0%) 19 (10.8%)
Pre-chemotherapy mN stage
0 119 (59.5%) 108 (61.4%)
1 47 (23.5%) 40 (22.7%)
2 34 (17.0%) 28 (15.9%)
Metabolic nodal response (mNR)
No avid nodes 111 (55.5%) 102 (58.0%)
CMR 38 (19.0%) 35 (19.9%)
PMR 9 (4.5%) 8 (4.54%)
SMD 25 (12.5%) 20 (11.4%)
PMD 9 (4.5%) 6 (3.41%)
de novo avid nodes 8 (4.00%) 5 (2.84%)
mTR
% Reduction SUVmax
(median, IQR)
42.4%
(12.8–60.6%)
45.5% (15.8–62.9%)
CMR 15 (7.50%) 15 (8.53%)
T stage (clinical or
pathological)
Clinical T stage Pathological T stage,
ypT
1b 5 (2.50%) 29 (16.5%)
2 34 (17.0%) 20 (11.4%)
3 133 (66.5%) 116 (65.9%)
4 28 (14.0%) 11 (6.25%)
N stage (clinical or
pathological)
Clinical N stage Pathological N stage,
ypN
0 64 (32.0%) 67 (38.1%)
1 83 (41.5%) 43 (24.4%)
2 47 (23.5%) 38 (21.6%)
3 6 (3.00%) 28 (15.9%)
ypV NA
0 102 (58.0%)
1 73 (41.5%)
Not known 1
Eur Radiol (2019) 29:6717–67276720
These proportions were less than the development cohort,
in which 11 of 43 (25.6%) patients with avid nodes had an
abandoned resection, compared with 15 of 197 (7.61%) with-
out. Rates of abandoned resections halved from 10.5 to
5.32%.
Prognosis
Two patients (1.06%) died in hospital of post-operative com-
plications and were excluded. Of the remaining 176 patients
(Table 1), 55 died (31.3%) and 59 (33.5%) developed recur-
rence during follow-up. Median OS, DFS, and recurrence
were not reached (respective 95%CI 1067 days—not reached;
770—not reached; 872—not reached). Median follow-up was
783 days (737–886).
On multivariate Cox analysis, the presence of avid nodes
following NAC was associated with death and recurrence fol-
lowing resection: OS HR 2.46 (1.34–4.51; p = 0.004), DFS
HR 1.90 (1.10–3.31; p = 0.022), and time to recurrence HR
2.02 (1.11–3.66; p = 0.021; Table 3; Fig. 1). This was inde-
pendent of similar negative associations with progressive ypN
stage. No other factors, including mTR (either reduction in
SUVmax, or PERCIST), were independently associated with
prognosis. There were no clinically or statistically significant
differences when mNR was quantified using mN stage after
NAC (i.e., the number of avid nodes). These HR were similar
to the development cohort: OS 1.75 (0.99–3.07; p = 0.053),
DFS 2.03 (1.16–3.55; p = 0.013), and recurrence 2.06 (1.10–
3.83; p = 0.023).
Hybrid pathological metabolic nodal stage
As bothmNR and ypN independently predicted prognosis, we
considered a composite. Overall 109 patients had nodal me-
tastases (ypN+), while 38 had avid nodes (mN+). Considering
post-NAC mN, a predictor of ypN, there were 31 true posi-
tives, 7 false positives, 78 false negatives, and 60 true nega-
tives. mNR was 28.4% sensitive (20.2–37.9), and 89.5% spe-
cific (79.7–95.7), PPV 81.6% (76.4–90.5), and NPV 43.5%
(40.0–47.0).
This ypNmN stage was associated with prognosis (Table 3;
Fig. 2): relative to pN0mN0 disease, patients with non-avid
nodal metastases (ypN + mN−) had a worse prognosis.
However, prognosis was even worse for patients with avid
nodal metastases (ypN + mN+). Interestingly, the small num-
ber with ypN-mN+ disease (i.e., presumed false avid positive)
demonstrated a trend towards worse prognosis for DFS
(p = 0.085) with significantly worse recurrence, suggesting
the possibility of pathologically missed micro-metastases.
Predicting early recurrence and death
One hundred twenty-nine of 161 (78.2%) patients were alive
and disease-free at 1 year, reducing to 68 of 128 (53.1%) at
2 years. On multivariate regression, lack of complete mNR
was associated with recurrence and death at both time points:
OR 4.18 (1.56–11.2; p = 0.004) and 3.63 (1.26–10.5;
p = 0.017) respectively. This was again independent of asso-
ciations with ypN (Table 4). The associations with ypN were
primarily for recurrence/death within 1 year, rather than
2 years. At 2 years, recurrence and death were associated with
hybrid pNmN stage.
At 1 year, 16 of 36 (44.4%) patients with persistent avid
nodes had either died or developed recurrence, compared with
20 of 129 (15.5%) without (p < 0.001 Fisher’s exact test).
Lack of a nodal CMR was 44.4% sensitive (27.9–61.9) and
84.5% specific (77.1–90.3), with PPV 44.4% (31.7–57.8) and
NPV 84.5 (80.1–88.1).
At 2 years, 20 of 27 (74.1%) patients with persistent avid
nodes had either died or developed recurrence, compared with
38 of 99 without (38.4%; p = 0.001). Lack of nodal CMR was
34.5% sensitive (22.5–48.1) and 89.7% specific (79.9–95.8),
with PPV 74.1% (56.6–86.3) and NPV 61.6% (56.7–66.3).
Discussion
We previously reported lack of complete metabolic nodal re-
sponse of esophageal cancer to NAC to be a new and inde-
pendent predictor of disease progression to unresectable dis-
ease [1], death, and recurrence [2]. In this validation study of
an immediately consecutive cohort of 200 patients, we con-
firmed these associations and were able to risk stratify
Table 1 (continued)
Characteristic All patients
(n = 200)
Survival analysis
(n = 176)
ypL NA
0 101 (57.4%)
1 74 (42.0%)
Not known 1
Resection margin status
Clear 147 (83.5%)
Involved 29 (16.5%)
pTR
No response 137 (49.6%)
Response 38 (21.6%)
Not known 1
AC , adenocarcinoma; SCC , squamous cell carcinoma; AS ,
adenosquamous carcinoma (excluded from multivariate analysis as per-
fect separator); IQR, interquartile range; mTR, metabolic tumor response;
CMR, complete metabolic response; PMR, partial metabolic response;
SMD, stable metabolic disease; PMD, progressive metabolic disease;
ypT, pathological tumor stage after chemotherapy; ypN, pathological nod-
al stage; ypV, pathological venous invasion; ypL, pathological lymphatic
invasion; pTR, pathological tumor response
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recurrence and death within 1 and 2 years. Compared with our
development cohort, effect sizes were entirely consistent for
prognosis. That for unresectable disease while significant and
consistent, was less clear, reflective of a reduction in event rate
overall with time.
These findings have a number of implications. Most immedi-
ately,mNR appears to a simpleway to risk stratify patients before
surgery, firstly identifying patients at higher risk of occult disease
resulting in an abandoned resection. Guidelines presently
recommend restaging with CT to exclude disease progression
before surgery [16]. We previously reported PET-CT to be more
sensitive [1]; however, this still failed to identify incurable dis-
ease in 5% of our patients. Identifying lack of complete mNR
might allow these patients to undergo additional investigations
(such as laparoscopy, thoracoscopy, or magnetic resonance im-
aging). These patients may also benefit from more personalized
and realistic information about their immediate risk of an aban-
doned resection, and medium- and long-term prognosis if
Table 2 Disease progression:
multivariate binary logistic
regression
Characteristic Odds ratio (OR; 95%
confidence interval)
p
Progression to overt metastatic disease on PET-CT
Restaging mN
mN0 Ref
mN1 0.78 (0.08–7.38) 0.832
mN2 4.37 (1.03–18.6) 0.045
mTR
% reduction in SUVmax 0.11 (0.02–0.56) 0.008
Progression to unsuspected unresectable disease at surgery
Restaging mN
mN0 Ref
mN1 6.25 (1.24–31.6) 0.027
mN2 8.28 (1.59–43.2) 0.012
Grade
Well/moderate Ref
Poor 5.85 (1.14–30.0) 0.034
FDG-avid nodes after NAC
No Ref
Yes 7.67 (1.94–30.4) 0.004
Grade
Well/moderate Ref
Poor 0.17 (0.04–0.91) 0.038
Disease progression overall
Restaging mN
mN0 Ref
mN1 2.79 (0.78–10.0) 0.114
mN2 4.62 (1.48–14.4) 0.001
Staging N
0 Ref Ref
1+ 3.43 (0.0.73–16.1) 0.118
FDG-avid nodes after NAC
No Ref
Yes 3.84 (1.46–10.1) 0.006
Staging N
0 Ref
1+ 3.79 (0.83–17.2) 0.085
mN, metabolic nodal stage; NAC, neoadjuvant chemotherapy; mTR, metabolic tumor response; FDG,
fluorodeoxyglucose
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surgery is successful. While this may not routinely alter
practice—other than for patients unclear as to whether to proceed
with surgery—patients can receive more realistic information
before consenting to surgery. While there is little evidence or
consensus as to follow-up, mNR might be incorporated into
decision support tools for targeted surveillance, and future edi-
tions of the TNM classification. Finally, the suggestion that pa-
tients with avid nodal disease, seemingly in the absence of path-
ological nodal disease, have a worse prognosis than those with-
out either is notable. Such instances might be dismissed as false
positives on PET-CT, but the converse might be true, with these
instances identifying occult but viable nodal micrometastases.
Biologically, this statistical independence of pN and mNR
is intriguing. As evidenced by the prognostic significance of a
novel pNmN hybrid stage, avid nodal metastases confer a
worse prognosis than non-avid metastases. This suggests per-
sistent nodal avidity to be a surrogate of a worse cancer phe-
notype. While the reasons for nodal avidity are complex and
incompletely understood (perhaps reflecting mutational bur-
den disrupting glucose utilization, in conjunction with tumor
Table 3 Prognosis: multivariate Cox regression analysis
Characteristic Hazard ratio (HR; 95% confidence interval); p value
Overall survival Disease-free survival Time to recurrence
mNR
No avid nodes/CMR Reference Reference Reference
PMR/SMD/PMD 2.46 (1.34–4.51; 0.004) 1.90 (1.10–3.31; 0.022) 2.02 (1.11–3.66; 0.021)
ypT stage
1b Reference Reference Reference
2 0.51 (0.09–2.91; 0.449) 0.83 (0.21–3.21; 0.784) 0.96 (0.23–4.04; 0.953)
3 0.75 (0.22–2.61; 0.656) 0.83 (0.28–2.46; 0.739) 0.80 (0.24–2.66; 0.720)
4 1.45 (0.34–6.49; 0.594) 1.69 (0.46–5.22; 0.429) 1.62 (0.39–6.38; 0.509)
ypN stage
0 Reference Reference Reference
1 2.19 (0.81–5.95; 0123) 3.04 (1.26–7.32; 0.013) 3.19 (1.19–8.54; 0.021)
2 2.88 (1.07–7.74; 0.036) 3.78 (1.54–9.26; 0.004) 4.45 (1.66–12.1; 0.003)
3 3.81 (1.34–10.8; 0.012) 4.62 (1.81–11.8; 0.001) 4.21 (1.47–12.1; 0.007)
ypV stage
0 Not included as univariate p > 0.1 Reference Reference
1 0.90 (0.50–1.61; 0.715) 0.83 (0.44–1.57; 0.572)
ypL stage
0 Reference Reference Reference
1 1.34 (059–3.06; 0.488) 1.54 (0.72–3.29; 0.264) 1.80 (0.78–4.15; 0.167)
Resection margin
Clear Reference Reference Reference
Involved 2.00 (0.97–4.13; 0.062) 1.79 (0.95–3.38; 0.073) 1.43 (0.69–2.93; 0.333)
pTR
No response Reference Reference Reference
Response 0.69 (0.19–1.90; 0.390) 0.79 (0.32–1.94; 0.610) 0.83 (0.32–2.21; 0.715)
mTR
%Reduction SUVmax 0.79 (0.33–1.86; 0.584) 0.88 (0.40–1.92; 0.753 0.77 (0.34–1.76; 0.536)
pN Mn hybrid, adjusted for variables above other than pN and mNR
pN mN hybrid
pN0 mN0 Reference Reference Reference
pN– mN+ 1.91 (0.23–15.6; 0.546) 4.00 (0.83–19.4; 0.085) 5.60 (1.08–29.1; 0.040)
pN+ mN – 3.87 (1.68–8.89; 0.001) 5.75 (2.75–12.9; < 0.001) 6.86 (2.68–17.6; < 0.001)
pN+ mN+ 10.5 (4.37–25.2; < 0.001) 11.1 (4.68–26.1; < 0.001) 13.5 (5.00–36.5; < 0.001)
CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD, progressive metabolic disease; mNR,
metabolic nodal response; mTR, metabolic tumor response; ypT, pathological tumor stage after NAC; ypN, pathological nodal stage; ypV, pathological
venous stage; ypL, pathological venous stage; pTR, pathological tumor response
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Fig. 1 Disease-free survival and mNR after neoadjuvant chemotherapy; p values generated using log-rank test
Fig. 2 Disease-free survival pN mN hybrid stage after neoadjuvant chemotherapy; p values generated using log-rank test
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micro-environment, perfusion, and hypoxia), at a simplistic
level, it may be possible to infer chemo(in)sensitivity. We
previously reported primary tumor response on PET-CT
(mTR) to be an imperfect surrogate of pathological response
(pTR) [17], in agreement with other groups [18], including its
successful use within the MUNICON trial [19]. Esophageal
cancer comprises a limited number of cancer clones, which
vary genomically and probably phenotypically, including their
chemosensitivity and propensity to metastasize [20]. Nodal
metastases may therefore comprise just one or two selected
oligoclones [21, 22]. We, and other groups, have previously
reported dramatic clonal evolution within the primary tumor
during the selection pressure of NAC [23, 24], with chemo-
resistant clones tending to persist or emerge, while
chemosensitive clones are lost. Lack of mNR may therefore
be an indicator of chemo-resistant clones within resectable
lymph nodes, and therefore by extrapolation, a surrogate for
the occult distant nodal or hematogenousmicrometastases that
are responsible for recurrence. This hypothesis is supported by
evidence that nodal downstaging, evidenced by imaging in
conjunction with pN stage, represents an independent prog-
nostic marker, likely a surrogate of pathological nodal regres-
sion [25, 26]. Whether this plausibly might be used to guide
neoadjuvant and adjuvant therapy is unknown.
While this study provides temporal validation of mNR
as a biomarker, we acknowledge a number of limitations.
Firstly, this represents a single-center study with a degree
of subjectivity inherent to all imaging studies (although
Table 4 Predicting early
recurrence and death: multivariate
binary logistic regression
Characteristic Odds ratio (OR; 95% confidence interval; p value)
Within 1 year Within 2 years
mNR
No avid nodes/CMR Reference Reference
PMR/SMD/PMD 4.18 (1.56–11.2; 0.004) 3.63 (1.26–10.5; 0.017)
ypT stage
1b Reference Reference
2 0.50 (0.45–4.97; 0.556) 0.82 (0.11–6.01; 0.843)
3 0.30 (0.05–2.07; 0.217 1.23 (0.27–5.50; 0.789)
4 0.47 (0.05–4.54; 0.514) 5.18 (0.58–46.5; 0.142)
ypN stage
0 Reference Reference
1 18.5 (1.89–182; 0.012) 2.24 (0.65–7.77; 0.204)
2 49.7 (5.01–493; < 0.001) 2.93 (0.81–10.6; 0.101)
3 74.3 (6.66–829; < 0.001) 4.79 (1.14–20.1; 0.032)
ypL stage
0 Reference Reference
1 0.68 (0.190–2.43; 0.556) 1.54 (0.72–3.29; 0.332)
Resection margin
Clear Reference Reference
Involved 1.59 (0.54–4.71; 0.399) 2.91 (0.79–10.7; 0.108)
pTR
No response Reference Reference
Response 0.47 (0.09–2.55; 0.383) 1.36 (0.38–4.91; 0.637)
mTR
%Reduction SUVmax 1.06 (0.26–4.36; 0.993) 1.06 (0.28–4.09; 0.931)
pN mN hybrid adjusted for all variables above, other than ypN and mNR
pN mN hybrid
pN0 mN0 Reference Reference
pN − mN+ NA 11.4 (0.85–152; 0.067)
pN + mN− NA 3.47 (1.07–11.3; 0.039)
pN + mN+ NA 9.19 (2.15–39.3; 0.003)
CMR, complete metabolic response; PMR, partial metabolic response; SMD, stable metabolic disease; PMD,
progressive metabolic disease; mNR, metabolic nodal response; mTR, metabolic tumor response; ypT, patholog-
ical tumor stage; ypL, pathological venous stage; pTR, pathological tumor response
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one subject to a rigorous MDT process); whether these
findings can be generalized to other centers and imaging
platforms is not clear. However, similar results have been
reported from Japan [27] following largely platinum-based
NAC as a marker of overall survival (although recurrence
was not assessed). While we previously found no differ-
ences across reconstruction platforms [2], these, and other
variables (such as NAC regimen) inevitable of evolving
practice, may exert subtle effects we were unable to iden-
tify. We were also unable to reliably adjust for adjuvant
therapy, and there may be additional factors that we have
failed to identify. Secondly, detection biases have been
introduced by “on-demand” investigations for recurrence
rather than surveillance imaging. Thirdly, while we found
consistent direction and sizes of effect for prognosis com-
pared with our development cohort, we saw fewer patients
overall with occult unresectable disease resulting in an
abandoned resection. This probably reflects improvements
in care with time, and hence while the association
persisted, its effect size is likely to be less accurate, and
requires further validation.
In conclusion, in a cohort of 200 patients immediately
consecutive to our discovery cohort, we found lack of a
complete mNR (i.e., the development or persistence of av-
id nodes despite NAC) to again be an independent and
seemingly consistent marker of disease progression, recur-
rence, and death after surgery. This temporal validation
provides supportive evidence justifying the assessment of
mNR as a new candidate biomarker for these endpoints in
external validation sets. If supported, mNR might represent
a new mechanism by which to both risk stratify patients
and personalize therapy with esophageal and GEJ cancer.
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